Share

December 2014; 1 (4) EditorialOpen Access

The genetics of natalizumab hypersensitivity

One learns to itch where one can scratch

Olaf Stüve, Bernhard Hemmer
First published December 11, 2014, DOI: https://doi.org/10.1212/NXI.0000000000000052
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
606

Share

Article Information

vol. 1 no. 4 e52
DOI: 
https://doi.org/10.1212/NXI.0000000000000052
PubMed: 
25520959
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published December 11, 2014.
Copyright & Usage: 
© 2014 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Olaf Stüve, MD, PhD and
    2. Bernhard Hemmer, MD
  1. Olaf Stüve, MD, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. JAMA Neurology Therapeutic Advances in Neurological Disorders Clinical and Experimental Immunology MS Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Teva Pharmaceuticals Opexa Therapeutics

    Research Support, Government Entities:

    1. Merit Review Grant Department of Veterans Affairs

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Bernhard Hemmer, MD
    3. Scientific Advisory Boards:

    1. Advisory board member for trials conducted by Bayer, BiogenIdec, Roche, Novartis, MerckSerono, Chugai, GSK, Genentech.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Sponsoring was received from Bayer, BiogenIdec, Roche, Novartis, MerckSerono for travelling and talks

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Anti-KIR4.1 antibody testing in MS (2) Genetic factors influencing the development of NABs

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Gerson Lehrman Group

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from Bayer, BiogenIdec, Roche, Novartis, MerckSerono, Metanomics, Chugai Pharmaceuticals and Protagen.

    Research Support, Government Entities:

    1. Deutsche Forschungsgemeinschaft, Bundesministerium f?r Bildung und Forschung, European Community.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Competence Network for Multiple Sclerosis Synergy Excellence Cluster German Research Foundation Bundesministerium f?r Bildung und Forschung

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas, TX; Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas, TX; Department of Neurology (O.S., B.H.), Klinikum rechts der Isar, Technische Universität München, Germany; and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Munich, Germany.
  1. Correspondence to Dr. Stüve: olaf.stuve{at}utsouthwestern.edu

Article usage

Article usage: December 2014 to October 2023

AbstractFullPdfSource
Dec 20141892563Highwire
Jan 2015521221Highwire
Jan 201504715pmc
Feb 201513116Highwire
Feb 20150113pmc
Mar 20151235Highwire
Mar 20150122pmc
Apr 20151951Highwire
Apr 2015071pmc
May 20151704Highwire
May 20150199pmc
Jun 201512133Highwire
Jun 20150122pmc
Jul 20152132Highwire
Jul 2015061pmc
Aug 20152923Highwire
Aug 2015031pmc
Sep 20151344Highwire
Sep 20150143pmc
Oct 20151844Highwire
Oct 20150121pmc
Nov 20151233Highwire
Nov 20150142pmc
Dec 20151000Highwire
Dec 20150145pmc
Jan 20161262Highwire
Jan 20160104pmc
Feb 20161941Highwire
Feb 2016052pmc
Mar 20161131Highwire
Mar 2016083pmc
Apr 20162760Highwire
Apr 20160104pmc
May 20161460Highwire
May 2016050pmc
Jun 201620513Highwire
Jun 2016083pmc
Jul 20161111Highwire
Jul 2016010pmc
Aug 20161400Highwire
Aug 2016071pmc
Sep 20161220Highwire
Sep 20160123pmc
Oct 2016610Highwire
Oct 20160134pmc
Nov 20161424Highwire
Nov 20160102pmc
Dec 2016810Highwire
Dec 20160100pmc
Jan 2017912Highwire
Jan 20170101pmc
Feb 2017320Highwire
Feb 2017022pmc
Mar 2017600Highwire
Mar 2017061pmc
Apr 2017311Highwire
Apr 2017077pmc
May 2017710Highwire
May 2017189pmc
Jun 2017201Highwire
Jun 2017022pmc
Jul 2017410Highwire
Jul 2017022pmc
Aug 2017511Highwire
Aug 2017066pmc
Sep 2017701Highwire
Sep 201751116pmc
Oct 2017411Highwire
Oct 201721516pmc
Nov 2017401Highwire
Nov 201701010pmc
Dec 20171123Highwire
Jan 2018051Highwire
Feb 2018461Highwire
Mar 20180131Highwire
Apr 20180225Highwire
Apr 2018045pmc
May 20182162Highwire
Jun 20182342Highwire
Jun 20182910pmc
Jul 20180302Highwire
Aug 20181262Highwire
Aug 201811112pmc
Sep 2018051Highwire
Oct 20181192Highwire
Nov 20180261Highwire
Dec 20182630Highwire
Jan 20191522Highwire
Feb 20192652Highwire
Mar 20196266Highwire
Apr 2019137Highwire
May 2019395Highwire
Jun 2019289Highwire
Jul 20191181Highwire
Aug 2019255Highwire
Sep 2019124Highwire
Oct 2019092Highwire
Nov 2019172Highwire
Dec 2019175Highwire
Jan 20200114Highwire
Feb 2020081Highwire
Mar 2020093Highwire
Apr 2020022Highwire
May 20200132Highwire
Jun 2020032Highwire
Jul 2020061Highwire
Aug 2020035Highwire
Sep 2020053Highwire
Oct 2020162Highwire
Nov 2020146Highwire
Dec 2020144Highwire
Jan 20212116Highwire
Feb 2021034Highwire
Mar 2021131Highwire
Apr 2021056Highwire
May 2021262Highwire
Jun 2021062Highwire
Jul 2021364Highwire
Aug 2021075Highwire
Sep 2021184Highwire
Oct 202121516Highwire
Nov 202111013Highwire
Dec 20210165Highwire
Jan 2022161Highwire
Feb 20221151Highwire
Mar 20221131Highwire
Apr 2022063Highwire
May 202221010Highwire
Jun 20220117Highwire
Jul 2022190Highwire
Aug 20221172Highwire
Sep 202201913Highwire
Oct 20221136Highwire
Nov 202224220Highwire
Dec 20220104Highwire
Jan 20230316Highwire
Feb 20231193Highwire
Mar 2023175Highwire
Apr 2023155Highwire
May 20231107Highwire
Jun 2023092Highwire
Jul 20232146Highwire
Aug 2023056Highwire
Sep 2023181Highwire
Oct 20230282Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles